Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has issued an announcement.
Guangzhou Baiyunshan Pharmaceutical Holdings announced that its consolidated subsidiary, Guangzhou Baiyunshan Biological Products Co., has received a drug registration certificate from China’s National Medical Products Administration for a lyophilized human rabies vaccine (Vero cell) for injection, classified as a preventive biological product. The approval, valid until December 2030, allows the subsidiary to act as both marketing authorization holder and manufacturer of the rabies vaccine, reinforcing the group’s position in the vaccine segment and potentially expanding its revenue base in the preventive healthcare market.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company is a major Chinese pharmaceutical group with shares listed in Shanghai and Hong Kong, engaged in the research, development, production and sale of medicines and biological products. Through its subsidiary Guangzhou Baiyunshan Biological Products Co., the group focuses on preventive biological products, contributing to China’s public health and vaccine markets.
YTD Price Performance: 5.55%
Average Trading Volume: 1,244,102
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.35B
Learn more about 0874 stock on TipRanks’ Stock Analysis page.